Our data demonstrate that SCDi administration reverses the AD-associated shift from resting to activated/disease states, suggesting that an SCD-controlled balance between saturated and monounsaturated fatty acids is a key regulator of microglial activation. The gene discussed is SCD; the disease is Alzheimer disease.